Table 2.
Effect of psychological co-morbidity on outcomes of patients with Crohn’s disease and ulcerative colitis
| Outcome | With psychiatric co-morbidity % | Without psychiatric co-morbidity % | Adjusted odds ratio† (95% CI) |
|---|---|---|---|
| Crohn’s disease | |||
| Surgery | 24 | 18 | 1.27 (1.03 – 1.58) |
| IBD-related hospitalization | 54 | 33 | 1.05 (0.88 – 1.26) |
| All-cause hospitalization | 83 | 54 | 1.48 (1.19 – 1.83) |
| Corticosteroids use | 56 | 34 | 1.83 (1.57 – 2.13) |
| Immunomodulator use | 37 | 28 | 1.43 (1.21 – 1.67) |
| Anti-TNF agent use | 19 | 16 | 1.17 (0.96 – 1.43) |
| Ulcerative colitis | |||
| Surgery | 11 | 10 | 1.01 (0.80 – 1.29) |
| IBD-related hospitalization | 28 | 22 | 0.77 (0.63 – 0.93) |
| All-cause hospitalization | 74 | 49 | 1.28 (1.07 – 1.52) |
| Corticosteroids use | 44 | 31 | 1.42 (1.22 – 1.64) |
| Immunomodulator use | 20 | 18 | 1.16 (0.97 – 1.39) |
| Anti-TNF agent use | 7 | 6 | 1.15 (0.86 – 1.53) |
IBD – Inflammatory bowel diseases; TNF – tumor necrosis factor
†
Adjusted for age, age at first diagnosis code for IBD, gender, modified Charlson co-morbidity index, duration of follow-up, and propensity score